MyCartis said that the new company, Antelope Dx, is developing a home test to diagnose Chlamydia trachomatis and Neisseria gonorrhea.
After reviewing more than 100 studies, the panel issued recommendations focused on women with a personal or family history of BRCA1/2-related cancers or high-risk ancestry.
The firm provided updates on its bacterial pathogen detection and antimicrobial resistance testing for bacterial isolates and a direct-from-urine test.
MX3 Diagnostics' saliva test conducts electrochemical measurements of the ionic density of saliva to enable a quick response to dehydration concerns.
Nasdaq told the company that as of June 30 its shareholder equity does not meet the minimum $2.5 million required for its shares to remain listed on the exchange.
The company recently launched an automated microbiology system in its Marlborough, Massachusetts laboratory using instruments from automation firm COPAN.